Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | STS | P08842 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | HRH2 | P25021 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119649 | 1.00 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL29260056 | 0.94 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL21069737 | 0.94 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL22609548 | 0.94 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL31085811 | 0.94 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL29267051 | 0.94 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL14497257 | 0.94 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL24480809 | 0.93 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL24480657 | 0.92 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL21876995 | 0.91 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4640686-A1 | DEGRADER FOR DEGRADING BRD PROTEIN AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Innocure Therapeutics, Inc. (KR) | 2025-10-29 | — | — | EP | disclosed |
| US-20240383874-A1 | BENZENE RING DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. | 2024-11-21 | — | — | US | disclosed |
| EP-4444717-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | University of Florida Research Foundation, Incorporated (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2024112122-A1 | DEGRADER FOR DEGRADING BRD PROTEIN AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 주식회사 이노큐어테라퓨틱스 | 2024-05-30 | — | — | WO | disclosed |
| CN-118076607-A | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2024-05-24 | — | — | CN | disclosed |
| CN-117425646-A | Phosphono derivative, composition thereof and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-01-19 | — | — | CN | disclosed |
| US-20230348427-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2023-11-02 | — | — | US | disclosed |
| US-20230348427-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2023-11-02 | — | — | US | disclosed |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| CN-116529248-A | Benzene ring derivative, composition and pharmaceutical application thereof | 四川海思科制药有限公司 | 2023-08-01 | — | — | CN | disclosed |
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| WO-2008150799-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| CN-101198590-A | Novel pyridine derivative and pyrimidine derivative (3) | EISAI R&D MAN CO LTD (JP) | 2008-06-11 | — | — | CN | disclosed |
| WO-2008025736-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | ABBOTT GMBH & CO. KG (DE) | 2008-03-06 | — | — | WO | disclosed |
| EP-1889836-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3) | Eisai R&D Management Co., Ltd. (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-5814636-A | TREATMENT AND PROPHYLAXIS OF THROMBOTIC DISEASES | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1998-09-29 | — | — | US | disclosed |
| EP-0721941-A1 | NOVEL COMPOUND HAVING PLATELET AGGREGATION INHIBITOR EFFECT | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1996-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348427-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | AR, NR5A1, SHBG | SMN1; SMN2 3395/4885NPC1 419/4885RAB9A 2449/4885 |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | SMN1; SMN2 2982/4885NPC1 2713/4885RAB9A 1901/4885 |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | SMN1; SMN2 3928/4885NPC1 2673/4885RAB9A 4332/4885 |
| US-20240383874-A1 | BENZENE RING DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | AR, SF3B5, SF3B1 | SMN1; SMN2 884/4885NPC1 933/4885RAB9A 1759/4885 |
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | HGF, MET, FLT4 | SMN1; SMN2 4771/4885NPC1 2775/4885RAB9A 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.